drugset / Trial / NCT03287414
Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to investigate the safety, tolerability and efficacy of VAY736 as potential therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
Timeline
- Start
- 2017-12-20
- Primary completion
- 2020-11-25
- Completion
- 2022-02-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ianalumab | Monoclonal antibody | 300 mg | Subcutaneous |
| Background | Nintedanib | Small molecule | — | — |
| Background | Pirfenidone | Small molecule | — | — |